Trial reportThe Canadian journal of urology2026
Efficacy of vaginal androgen combined with pelvic floor muscle training for stress urinary incontinence in postmenopausal women: a randomized-controlled trial.
Trial report in The Canadian journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesPostmenopausal women with stress urinary incontinence (SUI) exhibit low androgen expression. This study aimed to evaluate the efficacy and safety of vaginal androgen combined with pelvic floor muscle training (PFMT) in the treatment of SUI in postmenopausal women.
methodsPostmenopausal women with SUI were recruited from Hainan West Central Hospital between January 2024 and March 2025. Participants were randomly assigned in a double-blind manner to receive either vaginal androgen cream combined with PFMT (treatment group) or a visually identical placebo cream (without androgens) combined with PFMT (control group). The vaginal cream was applied to the vaginal wall at a dose of 0.5 g per application, twice weekly for a total of 10 applications, while PFMT was conducted for 8 weeks. The clinical efficacy and safety were compared between the two groups.
resultsA total of 61 patients were finally enrolled, with 31 in the treatment group and 30 in the control group. At both 3-month and 6-month follow-ups, the treatment group demonstrated significantly lower values in daily pad usage (p < 0.05), 24-h pad test scores (p < 0.05), and ICIQ-UI SF scores (p < 0.05) compared to the control group. The improvement rate of urinary incontinence was significantly higher in the treatment group (p < 0.05). Compared to baseline, the treatment group showed statistically significant reductions in all three outcome measures (all p < 0.05). No severe adverse events were reported in either group during the treatment period.
conclusionsAndrogen therapy combined with PFMT significantly improved the urinary incontinence remission rate in postmenopausal women with SUI, with no severe adverse effects observed. These findings suggest that androgen therapy may represent a novel therapeutic approach for SUI management in postmenopausal women. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR2300078752 in the Chinese Clinical Trial Registry.
Indexed as
Identifiers
41800510What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.